{"id":{"repo_id":"nus","oai_identifier":"oai:scholarbank.nus.edu.sg:10635/80239"},"canonical_url":"https://search.dev.ndltd.org/etd/nus/oai:scholarbank.nus.edu.sg:10635/80239","repository":{"repo_id":"nus","name":"National University of Singapore","base_url":"https://scholarbank.nus.edu.sg/oai/request"},"display":{"title":"HISTAMINERGIC H3 AND CANNABINOID CB1 RECEPTORS IN DEMENTIA","abstract":"This thesis examined neurochemical status and potential therapeutic roles of Histaminergic H3 and Cannabinoid CB1 receptors in neurodegenerative diseases. Based on neurochemical investigations in postmortem human brain samples, the status of H3 receptors remain unchanged under vascular dementia or mixed dementia pathology, and may serve as a therapeutic target for cognitive deficits. Measurements of CB1 receptors in postmortem brain samples of Lewy body dementia patients indicate the possible relationship between CB1 loss and amyloid plaque burdens as well as synaptic deficits. Furthermore, the effect of CB1 inverse agonists suppressing the non-amyloidogenic APP cleavage mediated by muscarinic agonist in SH-SY5Y neuroblastoma cell line suggest the loss of protection against A ß pathology when CB1 inverse agonists are co-administrated with cholinergic neurotransmission enhancements.","abstract_html":"This thesis examined neurochemical status and potential therapeutic roles of Histaminergic H3 and Cannabinoid CB1 receptors in neurodegenerative diseases. Based on neurochemical investigations in postmortem human brain samples, the status of H3 receptors remain unchanged under vascular dementia or mixed dementia pathology, and may serve as a therapeutic target for cognitive deficits. Measurements of CB1 receptors in postmortem brain samples of Lewy body dementia patients indicate the possible relationship between CB1 loss and amyloid plaque burdens as well as synaptic deficits. Furthermore, the effect of CB1 inverse agonists suppressing the non-amyloidogenic APP cleavage mediated by muscarinic agonist in SH-SY5Y neuroblastoma cell line suggest the loss of protection against A ß pathology when CB1 inverse agonists are co-administrated with cholinergic neurotransmission enhancements.","abstract_has_math":false,"creators":["SHENG YUAN"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2014,"date_issued":"2014-01-24","date_published":"2014-01-24","updated_at":"2026-07-24T03:31:51Z","subjects":["dementia, Histaminergic H3 receptor, Cannabinoid CB1 receptor, amyloid pathology, neurotransmitter, clinical correlation"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["SHENG YUAN"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.issued","label":"Date","values":["2014-01-24"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["https://scholarbank.nus.edu.sg/handle/10635/80239"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["dementia, Histaminergic H3 receptor, Cannabinoid CB1 receptor, amyloid pathology, neurotransmitter, clinical correlation"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://scholarbank.nus.edu.sg/bitstreams/f5e9130d-01f6-43f6-b744-664f2c60d7b2/download"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["This thesis examined neurochemical status and potential therapeutic roles of Histaminergic H3 and Cannabinoid CB1 receptors in neurodegenerative diseases. Based on neurochemical investigations in postmortem human brain samples, the status of H3 receptors remain unchanged under vascular dementia or mixed dementia pathology, and may serve as a therapeutic target for cognitive deficits. Measurements of CB1 receptors in postmortem brain samples of Lewy body dementia patients indicate the possible relationship between CB1 loss and amyloid plaque burdens as well as synaptic deficits. Furthermore, the effect of CB1 inverse agonists suppressing the non-amyloidogenic APP cleavage mediated by muscarinic agonist in SH-SY5Y neuroblastoma cell line suggest the loss of protection against A ß pathology when CB1 inverse agonists are co-administrated with cholinergic neurotransmission enhancements."]},{"key":"dc:format.checksum.md5","label":"Dc Format Checksum Md5","values":["2f5f90de128349e4fc3927037c9aa64c","e5d811d97420639de06f0833306ac7d4"]},{"key":"dc:title","label":"Title","values":["HISTAMINERGIC H3 AND CANNABINOID CB1 RECEPTORS IN DEMENTIA"]}]}],"canonical_facts":{"dc:creator":["SHENG YUAN"],"dc:date.issued":["2014-01-24"],"dc:description.abstract":["This thesis examined neurochemical status and potential therapeutic roles of Histaminergic H3 and Cannabinoid CB1 receptors in neurodegenerative diseases. Based on neurochemical investigations in postmortem human brain samples, the status of H3 receptors remain unchanged under vascular dementia or mixed dementia pathology, and may serve as a therapeutic target for cognitive deficits. Measurements of CB1 receptors in postmortem brain samples of Lewy body dementia patients indicate the possible relationship between CB1 loss and amyloid plaque burdens as well as synaptic deficits. Furthermore, the effect of CB1 inverse agonists suppressing the non-amyloidogenic APP cleavage mediated by muscarinic agonist in SH-SY5Y neuroblastoma cell line suggest the loss of protection against A ß pathology when CB1 inverse agonists are co-administrated with cholinergic neurotransmission enhancements."],"dc:format.checksum.md5":["2f5f90de128349e4fc3927037c9aa64c","e5d811d97420639de06f0833306ac7d4"],"dc:identifier.uri":["https://scholarbank.nus.edu.sg/bitstreams/f5e9130d-01f6-43f6-b744-664f2c60d7b2/download"],"dc:relation.isreferencedby":["https://scholarbank.nus.edu.sg/handle/10635/80239"],"dc:subject":["dementia, Histaminergic H3 receptor, Cannabinoid CB1 receptor, amyloid pathology, neurotransmitter, clinical correlation"],"dc:title":["HISTAMINERGIC H3 AND CANNABINOID CB1 RECEPTORS IN DEMENTIA"],"dc:type":["Thesis"]},"updated_at":"2026-07-24T03:31:51Z"}